Cannabis use and later life outcomes David M. Fergusson & Joseph M. Boden Addiction, 2008, 103, 969–976 doi : 10.1111/j.1360-0443.2008.02221.x ABSTRACT Aim : To examine the associations between the extent of cannabis use during adolescence and young adult-hood and later education, economic, employment, relationship satisfaction and life satisfaction outcomes. Design A longitudinal study of a New Zealand birth cohort studied to age 25 years. Measurements : Measures of : cannabis use at ages 14–25; university degree attainment to age 25; income at age 25; welfare dependence during the period 21–25 years; unemployment 21–25 years; relationship quality; life satisfaction. Also, measures of childhood socio-economic disadvantage, family adversity, [...]
Lire la suiteThe Role of Cannabis within an Emerging Perspective on Schizophrenia Jegason P. Diviant, Jacob M. Vigil, and Sarah S. Stith Medicines, 2018, 5, 86, 1-11. doi : 10.3390/medicines5030086 Abstract Background : Approximately 0.5% of the population is diagnosed with some form of schizophrenia, under the prevailing view that the pathology is best treated using pharmaceutical medications that act on monoamine receptors. Methods : We briefly review evidence on the impact of environmental forces, particularly the effect of autoimmune activity, in the expression of schizophrenic profiles and the role of Cannabis therapy for regulating immunological functioning. Results : A review of the literature shows that phytocannabinoid consumption may [...]
Lire la suitePsychedelics : Where we are now, why we got here, what we must do Sean J. Belouin, Jack E. Henningfield Neuropharmacology, 2018, 142, 7e19 https://doi.org/10.1016/j.neuropharm.2018.02.018 a b s t r a c t The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was [...]
Lire la suiteComment le cannabis peut favoriser les troubles psychotiques : conséquences, dépistage et prise en charge Alain Dervaux L’Information Psychiatrique, 2019, 95, (8), 672-678 * Travail présenté aux 37es journées de la Société de l’Information Psychiatrique, Antibes, 4-6 octobre 2018. Résumé Les relations complexes entre cannabis et psychoses ont fait l’objet de nombreux travaux depuis une vingtaine d’années. La consommation de cannabis peut s’accompagner de symptômes psychotiques chez certains sujets (jusqu’à 15 % des consommateurs) qui disparaissent avec l’élimination du -9-THC de l’organisme. Elle peut aussi augmenter par deux le risque de troubles psychotiques, notamment de schizophrénie. Le risque est d’autant plus élevé que la consommation de cannabis [...]
Lire la suiteLong-Term Pot Smoking Doesn’t Seem to Harm Health : Study Mandy Oaklander, The TIME, june 7, 2016 https://time.com/4359757/pot-smoking-marijuana-cannabis-health/?fbclid=IwAR1KRAo13u_0iDCYsWwYDd7_HwwFSRX8wkBQcWtgq1VneRwAfmdQwCY2Gw0 Getty Images By Mandy Oaklander June 7, 2016 Even after years of heavy use, marijuana doesn’t seem to have much of an impact on the physical health of the body. So finds a recent study published in JAMA Psychiatry, which analyzed data from a group of 1,037 New Zealanders followed from their birth until age 38. The researchers, led by Madeline Meier of Arizona State University, looked at whether cannabis use from age 18 to 38 was linked to several aspects of physical health, which were measured at [...]
Lire la suiteMedicinal cannabis not proven in mental health, study finds Kate Kelland Reuters, Health News, October 28, 2019 LONDON (Reuters) - Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution, researchers said on Monday. In a review of scientific studies that analyzed the impact of medicinal cannabinoids on six mental health disorders, the researchers found “a lack of evidence for their effectiveness.” Their findings have important implications for countries such as the United States, Australia, Britain and Canada, where medical cannabis is being made available for patients with certain [...]
Lire la suiteCould cannabidiol be used as an alternative to antipsychotics ? Marc Fakhoury Journal of Psychiatric Research · May 2016 Doi : 10.1016/j.jpsychires.2016.05.013 Abstract Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the [...]
Lire la suiteCannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8 Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]
Lire la suiteMedical use of cannabis. Cannabidiol: a new light for schizophrenia ? Serena Deiana Drug Testing and Analysis, 2013, 5, (1), 46-51 doi: 10.1002/dta.1425. Abstract The medical properties of cannabis have been known for many centuries; its first documented use dates back to 2800 BC when it was described for its hallucinogenic and pain-relieving properties. In the first half of the twentieth century, a number of pharmaceutical companies marked cannabis for indications such as asthma and pain, but since then its use has sharply declined, mainly due to its unpredictable effects, but also for socio-political issues. Recently, great attention has been directed to the medical properties [...]
Lire la suiteCannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015 Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]
Lire la suite